Highest-materiality recent filing
BriaPro subsidiary reports 9-month net loss of $712K; going concern uncertainty
Net loss for 9 months ended April 30, 2026: $712,236, vs $519,804 in prior-year period.
BriaCell closes $4.7M best-efforts equity offering; 1.45M shares at $3.25 each
Gross proceeds ~$4.7M from sale of 1,449,300 common shares at $3.25/share in a best-efforts offering.
BriaPro subsidiary reports $472K net loss for six months; going concern risk
BriaPro net loss widened to $472,231 for six months ended Jan 31, 2026 vs $233,185 a year ago.
BriaCell transfers exclusive license for Soluble CD80 to BriaPro for 23,972,589 BriaPro shares, increasing stake to ~78%.
BriaCell closes $30M public offering of units; warrants trade under BCTXL
Closed public offering of 5,366,726 units at $5.59/unit for gross proceeds of ~$30M.
BriaPro subsidiary posts Q1 operating loss $258K, R&D spend jumps 5x, going concern doubt
Net loss $244,738 for three months ended Oct 31, 2025, vs $82,123 prior year; operating loss $258,445.
BriaPro subsidiary reports $740K loss; going concern doubt flagged by auditor
BriaPro net loss $740,216 for year ended July 31, 2025, accumulated deficit $1,180,425.
BriaCell closes $15M public offering of 12M units at $1.25/unit
Gross proceeds of $15M before fees; 12,000,000 units sold at $1.25 per unit.
BriaPro Therapeutics (2/3 owned by BriaCell) reports net loss of $519,804 for 9 months, cash only $1
Net loss of $519,804 for nine months ended April 30, 2025 vs. $316,517 in prior year period.
BriaCell closes $13.8M public offering of units with warrants
Gross proceeds of ~$13.8M from 3,066,666 units at $4.50/unit, including 399,999 from over-allotment
Net loss for six months ended Jan 31, 2025: $233,185; accumulated deficit $673,394.
BriaCell regains Nasdaq minimum bid price compliance; delisting risk resolved
Received Nasdaq notice of compliance with $1.00 minimum bid price requirement on Feb 12, 2025.
BriaCell closes $5.55M public offering of 7.4M units at $0.75/unit
Underwritten public offering of 7,400,000 units closed Dec 13, 2024; gross proceeds $5.55M.
BriaCell closes $5M offering of 5.1M shares and warrants at $0.975/unit
5,128,500 common shares and warrants to purchase 5,128,500 common shares sold at $0.975 per unit.
Patient with 'eye-bulging' orbital tumor and brain metastasis achieved complete resolution of temporal lobe lesion at 8 and 11 months on Bria-IMT plus checkpoint inhibitor.
BriaCell closes $8.5M public offering of 12.3M shares at $0.69 each
Gross proceeds of $8,504,250 from sale of 12,325,000 common shares at $0.69/share.
BriaCell reports median OS of 15.6 months in Phase 2 Bria-IMT study; FDA path cleared for Bria-PROS+
Median overall survival of 15.6 months in 25 patients receiving Phase 3 Bria-IMT formulation vs 6.7–9.3 months in literature controls.
Received Nasdaq deficiency letter on Aug 22, 2024; bid price below $1.00 for 30 consecutive business days.
BriaCell Quadruples PFS to 9.1 Months in Top Responder Metastatic Breast Cancer Patient
PFS extended to 9.1 months in top responder patient, quadruple historical controls (1.7-2.3 months).
BriaCell receives Nasdaq notice for failing $35M minimum MVLS requirement
Received Nasdaq letter on July 3, 2024, for MVLS below $35M for 33 consecutive business days.
BriaPro subsidiary reports $317K net loss, $1 cash, going concern doubt
Net loss of $316,517 for nine months ended April 30, 2024; zero revenue.
BriaCell raises $5.0M in registered direct offering with warrants; director participates
Gross proceeds of $5.0M from sale of 2,402,935 shares (or pre-funded warrants) and warrants for additional 2,402,935 shares.
BriaCell reports prelim OS up to 2x literature in ADC-refractory breast cancer subset
23 heavily pre-treated (median 6 prior therapies) advanced breast cancer patients, all failed ADCs (KADCYLA, ENHERTU, TRODELVY).
Patient with proptosis from orbital metastatic breast cancer had remarkable improvement and pain reduction after 3 cycles of Bria-IMT combo.
BriaCell receives FDA clearance for Bria-OTS IND; reports preclinical data at SITC
FDA authorized Bria-OTS IND for clinical study of off-the-shelf personalized breast cancer immunotherapy.
BriaPro subsidiary files financials; spinout of cancer assets completed Aug 31, 2023
BriaPro filed Jul 31, 2023 financials: $1 cash, zero revenue, inactive during period.
Median overall survival 13.5 months in BriaCell's Phase 2 study vs 6.7-9.8 months for similar advanced metastatic breast cancer patients in literature.
BriaCell closes spinout of BriaPro to shareholders; retains 66.6% stake
Closed plan of arrangement spinning out Bria-TILsRx™ and PKCδ inhibitors to BriaPro.
BriaCell closes spinout of BriaPro, distributes shares to existing shareholders
BriaCell completed spinout of BriaPro, receiving 2/3 ownership; shareholders get one BriaPro share and one new BriaCell share per old share.
BriaCell gets court approval for spin-out of BriaPro Therapeutics, effective Aug 31, 2023
Court approved spin-out of BriaPro Therapeutics with pipeline assets including Bria-TILsRx and PKCδ inhibitors.
BriaCell shareholders approve spinout of BriaPro Therapeutics with 98.9% support
Shareholders approved Arrangement to spin out BriaPro Therapeutics (Bria-TILsRx, PKCδ inhibitors) with 98.92% votes.
FDA approves BriaCell's registrational study design for Bria-IMT combo in advanced breast cancer
FDA approved primary and secondary endpoints, study design, and patient population for Bria-IMT plus checkpoint inhibitor in advanced metastatic breast cancer.
BriaCell to spin out pre-clinical assets into BriaPro; shareholders get 1 SpinCo share per each held
SpinCo to acquire Bria-TILsRx™ and PKCδ inhibitors from BriaCell.
BriaCell closes $4M strategic investment by Prevail Partners at $8.63/share
Issued 463,408 common shares to Prevail Partners for aggregate gross proceeds of $4 million.
BriaCell signs $4M stock purchase and CRO agreement with Prevail for pivotal breast cancer study
Prevail InfoWorks to serve as CRO for BriaCell's pivotal advanced metastatic breast cancer study, expected in 2023.
BriaCell presents positive Bria-IMT data at AACR; 15/18 alive, immune activation in anergic patients
15 of 18 patients enrolled since 2021 remain alive; survival compares favorably to 6.7-9.8 months in similar studies.
On November 23, 2024, Marc Lustig resigned from the board of directors of BriaCell Therapeutics Corp. (the “Company”)
Max materiality 0.85 · Median 0.65 · Most common event other_material